



31 January 2020

## WORLD CLASS TEAM NOW IN PLACE FOR 2020

Respiri Limited (ASX:RSH) (“Respiri” or the “Company”) wishes to confirm the appointment of a number of new key hires.

Please note the following appointments and existing staff adjustments made in January 2020:

1. Philippe Ludekens – General Manager Commercial Operations
2. Marc van Hoof – Technology strategy and development
3. Samaneh Sarraf Shirazi – Chief Research Officer

A brief summary of the above executive’s experience follows below.

### 1. PHILIPPE LUDEKENS

Philippe has enjoyed a 25+ year career in life sciences, specifically in the pharmaceutical industry, having worked with multiple organisations of varying sizes, cultures and therapeutic interests. Philippe has a strong commercial background in sales, key account management, marketing, including numerous product launches, and most recently in commercial operations as Senior Director for Gilead Sciences ANZ. Philippe will lead the sales, marketing and commercial efforts working with the rest of the senior management team to ensure a Q4 launch our eHealth SaaS offering.

### 2. MARC VAN HOOF

Marc is a senior technology advisor engaged by Respiri on a consultancy basis. Marc started the first Internet Data Centre in Australia; built content networks across Asia; has webcast a number of major concert series and managed a \$700M product line throughout Asia-Pacific. Marc is responsible for ensuring the timely and appropriate development of the wheezo SaaS platform and readying the Company for it’s SaaS strategy launch.


### 3. SAMANEH SARRAF SHIRAZI

Samaneh steps up to the executive team after 3 years as Respiri’s Chief Research Officer. Samaneh is an experienced research and development biomedical engineer with specialist skills in breath sound analysis. Samaneh has a PhD in biomedical engineering from the University of Manitoba in Canada and has more than 10 years’ experience in biomedical signal processing. Samaneh is responsible for the Company’s research program and for the management of its clinical trials.

I would like to welcome the new members of the team that we will continue to build and reinforce through calendar 2020. It is, indeed, now a world class team.

---End---

Contact:  
Marjan Mikel  
CEO/Managing Director  
[marjan@respiri.co](mailto:marjan@respiri.co)



## About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo® product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia.

## Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri's current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.